SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy. The collaboration will leverage Serotiny’s tMDP mining and design capabilities with Janssen’s antibody development and cell therapy expertise to create next generation CAR-based cell therapies that will potentially have improved therapeutic function and enhanced clinical benefit. The agreement was facilitated by Johnson & Johnson Innovation.